Page last updated: 2024-12-04

amifostine anhydrous

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2141
CHEMBL ID1006
CHEBI ID2636
SCHEMBL ID18464
MeSH IDM0585621

Synonyms (139)

Synonym
AC-1126
BIDD:GT0059
AB00053311-05
AB00053311-04
NSC296961 ,
DIVK1C_006743
NCIMECH_000622
NCI60_002485
smr000058413
ym-08310
MLS000028473
ethyol
s-{2-[(3-aminopropyl)amino]ethyl} dihydrogen thiophosphate
EU-0100029
ethanethiol, {s-[(3-aminopropyl)amino]-,} dihydrogen phosphate- (ester)
{s-[2-(3-aminopropylamino)ethyl]} phosphorothioate
{s-[2-[(3-aminopropyl)amino]ethyl]} dihydrogen phosphorothioate
2-(3-aminopropylamino)ethylsulfanylphosphonic acid
SPECTRUM_000332
SMP2_000335
brn 2088122
acide ((amino-3 propylamino)-2 ethyl)-s-phosphorothioique [french]
2-((3-aminopropyl)amino)-ethanethiol, dihydrogen phosphate ester
s-(2-((3-aminopropyl)amino)ethyl) dihydrogen phosphorothioate
s-omega-(3-aminopropylamino)ethyl dihydrogen phosphorothioate
s,2-(3-aminopropylamino)ethyl-phosphorothioic acid
s-2-(3-aminopropylamino)ethyl phosphorothioic acid
ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester)
apaetp
phosphorothioic acid, s-(2-(3-aminopropylamino)ethyl) ester
lopac-a-5922
NCGC00015073-01
CHEBI:2636 ,
amifostina
gammaphos
aminopropylaminoethyl thiophosphate
2-(3-aminopropylamino)ethyl thiophosphate
s-(2-(3-aminopropylamino)ethyl) phosphorothioate
s-[2-[(3-aminopropyl)amino]ethyl] dihydrogen phosphorothioate
ethanethiol, dihydrogen phosphate (ester)
ethiofos
wr 2721
phosphorothioic acid, s-[2-[(3-aminopropyl)amino]ethyl] ester
ethanethiol, dihydrogen phosphate- (ester)
phosphorothioic acid, s-[2-[(3-aminopropyl)amino]ethyl]ester
nsc-296961
wr 2721c
sapep
au-95722
s-[2-(3-aminopropylamino)ethyl] phosphorothioate
SPECTRUM5_001920
LOPAC0_000029
20537-88-6
C06819
amifostine
DB01143
amifostine anhydrous
amifostine [usan:inn:ban]
KBIO2_003380
KBIOSS_000812
KBIO1_001687
KBIO2_000812
KBIO2_005948
SPECPLUS_000647
NCGC00093549-02
NCGC00093549-01
ym 08310
wr2721
ethiofos anhydrous
NCGC00015073-02
HMS2090I03
2-(3-aminopropyl)aminoethyl phosphorothioate; wr2721
A 5922
NCGC00015073-04
CHEMBL1006
nsc-758236
HMS3260E19
A814662
2-(3-aminopropylamino)ethylsulfanylphosphonic acid;amifostine
nsc758236
pharmakon1600-01503081
dtxcid602585
dtxsid8022585 ,
tox21_110077
cas-20537-88-6
ethanethiol, 2-[(3-aminopropyl)amino]-, 1-(dihydrogen phosphate)
CCG-35734
NCGC00015073-03
ccris 9316
s 8744
acide ((amino-3 propylamino)-2 ethyl)-s-phosphorothioique
hsdb 7560
ila426l95o ,
unii-ila426l95o
amifostine ethiofos
FT-0622272
LP00029
amifostine [inn]
2-((3-aminopropyl)amino)ethanethiol 1-(dihydrogen phosphate)
phosphorothioic acid s-(2-((3-aminopropyl)amino)ethyl) ester
amifostine [jan]
amifostine [mi]
amifostine [hsdb]
amifostine [who-dd]
AKOS015895196
BRD-K73947551-001-01-0
HY-B0639
SCHEMBL18464
tox21_110077_1
NCGC00015073-05
NCGC00260714-01
tox21_500029
s-(2-((3-aminopropyl)amino)ethyl) o,o-dihydrogen phosphorothioate
AB00053311_06
2-(3-aminopropyl)aminoethyl phosphorothioate
({2-[(3-aminopropyl)amino]ethyl}sulfanyl)phosphonic acid
J-519582
sr-01000075680
SR-01000075680-1
mfcd00233058
J-013390
SR-01000075680-3
SR-01000075680-5
SBI-0050018.P003
HMS3713C06
ethyol;wr2721
2-(3-aminopropyl)aminoethylphosphorothioate
amifostine,(s)
s-2-(3-aminopropylamino)ethyl o,o-dihydrogen phosphorothioate
Q251698
AS-13020
BCP08957
2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate
SDCCGSBI-0050018.P005
NCGC00015073-15
amifostine (hydrate)
2-((3-aminopropyl)amino)-ethanethiol, dihydrogen phosphate ester (9ci)
EN300-2008949
Z1269145833

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Selectivity of protection by WR2721 is probably due to the preferential formation and uptake of the thiol metabolite 2-(3-aminopropylamino)ethanethiol (WR1065), which can inactivate toxic platinum-species inside the cell."( Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Boven, E; Holwerda, U; Pinedo, HM; Treskes, M; van der Vijgh, WJ, 1992
)
0.28
" injection of 200 mg/kg WR-2721 at 5 min prior to the administration of this combination enabled us to increase the CBDCA dose from a nontoxic level of 45 mg/kg to a normally toxic dose of 60 mg/kg in non-tumor-bearing BALB/c mice while maintaining the 5FU dose at 100 mg/kg."( Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.
Peters, GJ; Treskes, M; van der Vijgh, WJ; van der Wilt, CL; van Laar, JA, 1992
)
0.28
" The results suggest that DDTC may allow for increased dosages of tetraplatin by ameliorating the toxic side effects of the drug."( Reduction of tetrachloro(dl-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat.
Carfagna, PF; Chaney, SG; Chang, J; Holbrook, DJ, 1990
)
0.28
" When used adjunctively with oxygen radical generating chemotherapeutic agents in mice, however, WR2721 produces synergistic toxicity rather than attenuation of the toxic effects of such agents."( Mechanisms of synergistic toxicity of the radioprotective agent, WR2721, and 6-hydroxydopamine.
Schor, NF, 1988
)
0.27
" The 1/10 lethal dose in mice was slightly toxic to dogs; 1/10 of that dose was nontoxic."( Toxicity studies on the radioprotective agent WR-2721 in CDF1 mice and beagle dogs.
Dickie, BC; Glaza, SM; Greenspun, KS; Palmer, TE; Weltman, RH, 1985
)
0.27
" In conclusion, levamisole appears to be too toxic and non-specific to be useful in studying and regulating the metabolism, toxicity and radioprotection of WR-2721."( Modification of WR-2721 toxicity and radioprotection by an inhibitor of alkaline phosphatase.
Brown, DQ; Gold, J; Hardiman, J; Mann, DJ; Pittock, JW; Pogach, R; Shaw, LM, 1986
)
0.27
" WR-2721 can, therefore, increase the effectiveness of cisplatin therapy through selective protection against the toxic side effects of chemotherapy."( Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties.
Culo, F; Yuhas, JM, 1980
)
0.26
" The toxic LD50/30 was 3574 mg/kg."( Toxicity and radiation protective effect of WR-77913 in BALB/c mice.
Connor, AM; Grigsby, P; Mendiondo, OA, 1982
)
0.26
" We conclude that WR-2721 is a potentially toxic compound that produces no amelioration of cyclophosphamide toxicity in the doses used."( Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide.
Ayoob, MJ; Dritschilo, A; Smith, FP; Woolley, PV, 1983
)
0.27
" Dose modification factors (DMFs) were calculated as ratios of LD50 values."( Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution.
Anderson, K; Krohn, KA; Mahler, P; Menard, T; Nelson, NJ; Rasey, JS, 1984
)
0.27
" Toxicity assessments in the mouse yielded a LD50 of 297 mg/kg and in the rat 389 mg/kg."( Toxicity, biodistribution and radioprotective capacity of L-homocysteine thiolactone in CNS tissues and tumors in rodents: comparison with prior results with phosphorothioates.
Ali-Osman, F; Chin, L; Dwyer-Hansen, L; Grunbaum, Z; Krohn, KA; Livesey, J; Nelson, N; Rasey, JS; Spence, AM; Stein, D, 1995
)
0.29
" The results of this study will show that amifostine protects normal late and early progenitor cells for the toxic effects of cyclophosphamide derivatives while preserving their antileukaemic effects."( Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
Douay, L; Giarratana, MC; Gorin, NC; Hu, C, 1995
)
0.29
" There is also evidence that aminothiols are toxic to the germinal cell layer of the seminiferous tubules when given to sham-irradiated mice."( Comparative intestinal and testes toxicity of four aminothiols in irradiated and nonirradiated mice.
Eckstein, JM; Egan, JE; Heman-Ackah, LM; Jackson, WE; Kendrick, JM; Steel-Goodwin, L,
)
0.13
" An in vitro endothelial model of injury was developed to assess the direct toxic effects of CP, CP derivatives and CP metabolites on cultured endothelial cells."( Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury.
Kachel, DL; Martin, WJ, 1994
)
0.29
"Cisplatin is a nephrotoxic drug; however, agents that may make cisplatin therapy more safe and rewarding will be available in the near future."( Newer insights into cisplatin nephrotoxicity.
Anand, AJ; Bashey, B, 1993
)
0.29
"The mechanism of action, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of amifostine are reviewed."( Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora, JA; Siden, R, 1997
)
0.3
" It was shown that this compound can protect normal cells from the toxic effects of ionizing radiation and chemotheraphy without affecting the efficacy of the therapy."( [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
Chomiczewski, K; Jabłońska, H; Wrembel-Wargocka, J, 1996
)
0.29
" Our results confirm previous reports of the ability of amifostine to protect normal tissues from the toxic effects of chemotherapy drugs and now extend these observations to paclitaxel."( Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Capizzi, RL; Fernandes, D; Johnson, CS; List, AF; Paine-Murrieta, GD; Taylor, CW; Wang, LM, 1997
)
0.3
" Instead, patients in the control arms of some of the trials have been exposed to more prolonged use or increased dosage of toxic chemotherapy that placed them at greater risk of the toxicity the protective agent was designed to prevent (eg, cardiotoxicity in trials of dexrazoxane, myelosuppression or thrombocytopenia in trials of growth factors)."( Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.
Phillips, KA; Tannock, IF, 1998
)
0.3
" The main potentially dose-limiting adverse effect is hypotension, that is often asymptomatic."( Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).
Abbate, G; Auriemma, A; Catalano, G; Ciaramella, F; De Vita, F; Infusino, S; Iodice, P; Orditura, M; Roscigno, A,
)
0.13
" In conclusion, amifostine seems to be effective and safe when used as protective agent also in esophageal cancer."( Efficacy and safety profile of amifostine in the preoperative combined therapy of esophageal cancer patients.
Abbate, G; Belli, A; Catalano, G; Ciaramella, F; De Vita, F; Diadema, MR; Ferrigno, A; Formato, R; Musicò, M; Orditura, M,
)
0.13
" Recently, new strategies aiming to protect against cancer treatment toxicity have been developed, including the drug amifostine (Ethyol), which is suggested to protect normal tissues from the toxic effects of radiation and cytotoxic agents."( Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.
Eksborg, S; Jahnukainen, K; Jahnukainen, T; Salmi, TT; Söder, O; Svechnikov, K, 2001
)
0.31
"The nucleoside analog gemcitabine is a potent radiosensitizer of both tumor and normal mucosa, so severe toxic reactions have resulted from its combination with radiation in some clinical treatment schedules for pancreatic cancer."( WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment.
Crane, CH; Janjan, NA; Mason, KA; Milas, L; Phan, TP; Vrdoljak, E, 2001
)
0.31
" Although several approaches have been proposed to challenge the toxic action(s) of SM, no satisfactory treatment regimen has evolved."( Protective effects of amifostine and its analogues on sulfur mustard toxicity in vitro and in vivo.
Bhattacharya, R; Kulkarni, A; Kumar, P; Pant, SC; Pathak, U; Rao, PV; Tulsawani, RK; Vijayaraghavan, R, 2001
)
0.31
" The main side effect of idarubicin is free-radicals based cardiotoxicity."( Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine.
Błasiak, J; Gloc, E; Majsterek, I; Młynarski, W; Skórski, T; Stolarska, M; Woźniak, K, 2002
)
0.31
" The LD50 values of amifostine and DRDE-07 were determined following oral and intraperitoneal routes and the LD50 of SM diluted in PEG-300 was determined following dermal route."( In vivo protection by amifostine and DRDE-07 against sulphur mustard toxicity.
Jaiswal, DK; Kulkarni, AS; Kumar, P; Pathak, U; Raza, SK; Vijayaraghavan, R, 2002
)
0.31
" Xerostomia is a side effect of radiation therapy and, if not managed properly, can disrupt the patient's quality of life and lead to other health related issues."( Head and neck cancer: managing xerostomia and other treatment induced side effects.
Gosselin, TK; Pavilonis, H, 2002
)
0.31
"Renal injury is a common side effect of the chemotherapeutic agent ifosfamide."( Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells.
Springate, JE; Taub, M; Zaki, EL, 2003
)
0.32
"Cisplatin is not directly toxic to bone, but cisplatin nephrotoxicity leading to magnesium wasting may affect magnesium and calcium metabolism, both of which contribute to bone integrity."( Cisplatin nephrotoxicity affects magnesium and calcium metabolism.
Goren, MP, 2003
)
0.32
" At baseline, before each treatment cycle, and for 3 months after completing chemotherapy, patients were evaluated for evidence of neurotoxicity and other treatment-related adverse effects using three methods: standard clinical evaluation (National Cancer Institute common toxicity criteria [CTC] grading), a neurotoxicity questionnaire to assess symptoms and limitations imposed by peripheral neuropathy, and vibration perception threshold (VPT) testing."( Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Almadrones, L; Cella, DF; Donnelly, J; Herzog, TJ; McGuire, WP; Moore, DH; Waggoner, SE, 2003
)
0.32
" Four types of targeted adverse events were examined as to their occurrence and possible relationship with amifostine."( Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design.
Chico, IM; Fullmer, K; Hirsch, RL; Samuels, MA, 2003
)
0.32
" This is the first report focusing on amifostine related adverse effects leading to discontinuation of amifostine treatment."( Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Alberti, W; Bajrovic, A; Fehlauer, F; Mahlmann, B; Rades, D; Richter, E, 2004
)
0.32
"In 16/39 patients (41%) amifostine was discontinued due to severe adverse effects, which led to discontinuation of the phase III study."( Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Alberti, W; Bajrovic, A; Fehlauer, F; Mahlmann, B; Rades, D; Richter, E, 2004
)
0.32
" administration of amifostine during radiotherapy in head and neck cancer is associated with a high rate of serious adverse effects leading to discontinuation of amifostine treatment and sometimes delay of radiotherapy."( Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Alberti, W; Bajrovic, A; Fehlauer, F; Mahlmann, B; Rades, D; Richter, E, 2004
)
0.32
"Aminothiol amifostine (AMI) protects against toxic effects of both ionizing radiation and numerous anticancer drugs."( Amifostine protection against doxorubicin cardiotoxicity in rats.
Bokonjic, DR; Dobric, SL; Dogovic, NP; Dragojevic-Simic, VM; Jacevic, VM; Sinovec, SM; Vucinic, ZM, 2004
)
0.32
"Chemoprotective agents reduce the toxic side effects of chemotherapy agents such as cisplatin."( WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.
Blakley, BW; Burgio, DL; Church, MW; Gupta, AK, 2004
)
0.32
"Sulfur mustard (SM) is a highly toxic chemical warfare agent."( Novel S-substituted aminoalkylamino ethanethiols as potential antidotes against sulfur mustard toxicity.
Jaiswal, DK; Kulkarni, AS; Kumar, P; Pathak, U; Raza, SK; Vijayaraghvan, R, 2004
)
0.32
"Peripheral neurotoxicity is a dose-limiting side-effect of a number of effective chemotherapeutic agents."( Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation.
Geldof, AA; Heimans, JJ; Postma, TJ; Verstappen, CC,
)
0.13
"Daily treatment of outbred albino mice with gammafos in radioprotective doses of 300 and 500 mg/kg for 4 days produced a cumulative toxic effect."( Effect of melatonin, ascorbic acid, and succinic acid on the cumulative toxic effect of repeated treatment with gammafos (amifostine).
Komarova, SN; Kovtun, VY; Semenova, LA; Ushakov, IB; Vasin, MV, 2004
)
0.32
"Ototoxicity is a common side effect of high-dose cisplatin treatment."( High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ehrsson, H; Ekborn, A; Eksborg, S; Hansson, J; Laurell, G; Wagenius, G; Wallin, I, 2004
)
0.32
" The aim of this study was to evaluate and compare the toxic effects of Daunorubicin, in normal or liposomal formulation, used in combination with WR1065, the active metabolite of Amifostine, against normal and tumor cells."( Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells.
Calistri, E; Candoni, A; Damiani, D; Fanin, R; Michelutti, A; Russo, D; Stocchi, R; Tiribelli, M, 2006
)
0.33
" In the search for more effective and less toxic compounds, a number of analogues of DRDE-07 were synthesised and their protective efficacy was evaluated in mouse and rat models."( Evaluation of analogues of DRDE-07 as prophylactic agents against the lethality and toxicity of sulfur mustard administered through percutaneous route.
Anshoo, G; Kulkarni, AS; Malhotra, RC; Pant, SC; Pathak, U; Prakash, AO; Raza, SK; Satish, HT; Vijayaraghavan, R,
)
0.13
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Ototoxicity is an important and dose-limiting side-effect of cisplatin therapy."( Future opportunities in preventing cisplatin induced ototoxicity.
Balm, AJ; Beijnen, JH; Schellens, JH; van den Berg, JH, 2006
)
0.33
"Renal injury is a common side effect of the chemotherapeutic agent ifosfamide."( Ifosfamide toxicity in cultured proximal renal tubule cells.
Springate, J; Taub, M, 2007
)
0.34
" Amifostine is a well-known cytoprotective agent and has been widely used in clinical for protecting normal tissues from the toxic effects of chemotherapy and radiotherapy."( Amifostine protects bone marrow from benzene-induced hematotoxicity in mice.
Chen, Y; Liu, XH; Ren, XZ; Yang, KY; Yu, K,
)
0.13
" There were no reports of Grade >/=3 amifostine-related adverse events."( Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Christie, D; Kennedy, T; Law, A; Pellitteri, P; Wood, C; Yumen, O, 2007
)
0.34
"Paraquat (PQ) is a highly poisonous herbicide with a variety of toxic effects, most notably pulmonary fibrosis."( The effect of amifostine, a cytoprotective agent, on paraquat toxicity in mice.
Aks, S; Brand, R; Maloney, GE; Rhee, J; Sekosan, M; Wills, BK, 2007
)
0.34
"Current standard treatments for cancer are associated with major dose-limiting toxic effects on healthy tissue."( Prevention and treatment of regimen-related mucosal toxicity.
Bowen, JM, 2008
)
0.35
" Acute and late adverse effects were recorded using the RTOG score."( Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study.
Aebersold, D; Curschmann, J; Ghadjar, P; Goldblum, D; Greiner, R, 2008
)
0.35
" The treatment was well tolerated without major toxic reactions."( Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study.
Aebersold, D; Curschmann, J; Ghadjar, P; Goldblum, D; Greiner, R, 2008
)
0.35
" Differential toxicity study of SM and HN-3 reveals that both the compounds were more toxic by percutaneous route as compared to subcutaneous route."( Ameliorative effect of DRDE 07 and its analogues on the systemic toxicity of sulphur mustard and nitrogen mustard in rabbit.
Ganeshan, K; Gautam, A; Kumar, A; Kumar, P; Pathak, U; Prakash, CJ; Vijayaraghavan, R, 2010
)
0.36
" In the search for more effective and less toxic antidotes, various combinations were tried against SM induced toxicity and skin lesions."( Prophylactic efficacy of combination of DRDE-07 and its analogues with amifostine against sulphur mustard induced systemic toxicity.
Gautam, A; Gupta, A; Lomash, V; Pant, SC; Vijayaraghavan, R, 2010
)
0.36
"Early toxicity was overall low, proctitis being the most frequent side-effect (23."( Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy.
Giatromanolaki, A; Kalogeris, K; Koukourakis, MI; Kyrgias, G; Mavropoulou, S; Milioudis, N; Nassos, P; Panteliadou, M; Papadopoulou, A; Sivridis, E; Touloupidis, S, 2011
)
0.37
"HypoARC is feasible and safe for patients with low-risk prostate cancer and, considering also the high efficacy noted, a strong rationale is provided for the further evaluation of HypoARC in randomized trials."( Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy.
Giatromanolaki, A; Kalogeris, K; Koukourakis, MI; Kyrgias, G; Mavropoulou, S; Milioudis, N; Nassos, P; Panteliadou, M; Papadopoulou, A; Sivridis, E; Touloupidis, S, 2011
)
0.37
" However, the patients receiving amifostine suffer from severe dose-dependent adverse effects."( Improvement of the in vitro safety profile and cytoprotective efficacy of amifostine against chemotherapy by PEGylation strategy.
Ding, Y; Ji, T; Nie, G; Qi, S; Wang, H; Wei, J; Yang, X; Zhao, R; Zhao, X, 2016
)
0.43
" The aim of our study was to investigate amifostine effects on doxorubicin-induced toxic changes in rats."( The Efficacy of Amifostine against Multiple-Dose Doxorubicin-Induced Toxicity in Rats.
Bokonjić, D; Dobrić, S; Dragojević-Simić, V; Jaćević, V; Kovačević, A; Kuča, K; Nepovimova, E; Tatomirović, Ž; Vališ, M, 2018
)
0.48
" Thus, effective yet safe methods of radiation injury prophylaxis would be desirable."( Amifostine Prophylaxis in Irradiated Breast Reconstruction: A Study of Oncologic Safety In Vitro.
Buchman, LK; Buchman, SR; Cohen, MS; Donneys, A; Luby, AO; Lynn, JV; Nelson, NS; Subramanian, C; Urlaub, KM, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic properties of WR-2721 were investigated in 13 cancer patients given a 150 mg/M2 intravenous bolus dose of the drug."( Human pharmacokinetics of WR-2721.
Bonner, HS; Glover, DJ; Kligerman, MM; Norfleet, AL; Shaw, LM; Turrisi, AT; Weiler, C, 1986
)
0.27
" Validated analytic methodology to measure parent drug and pharmacologically active metabolites and pharmacokinetic studies are essential to the efficient performance and analysis of clinical studies."( Pharmacokinetic profile of amifostine.
Bonner, H; Lieberman, R; Shaw, LM, 1996
)
0.29
" Both amifostine and WR 1065 were rapidly cleared from the plasma (95% and 50% of the peak concentration within 1 h, respectively)."( Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Gall, HE; Korst, AE; van der Vijgh, WJ; Vermorken, JB, 1996
)
0.29
" Compared with a control group of patients who received carboplatin alone, the patients receiving the combination had a longer final half-life of ultrafilterable platinum species [5."( Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
Eeltink, CM; Fichtinger-Schepman, AM; Korst, AE; van der Sterre, ML; van der Vijgh, WJ; Vermorken, JB, 1997
)
0.3
"Findings of pharmacokinetic studies of amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) in animal models and in human cancer patients support the hypothesis that amifostine pharmacokinetics are nonlinear."( Pharmacokinetics of amifostine: effects of dose and method of administration.
Bonner, HS; Lieberman, R; Schiller, J; Schuchter, L; Shaw, LM, 1999
)
0.3
" In this study, the pharmacokinetic parameters of 5-FU are monitored in six patients, who received two chemotherapeutic courses of 2,600 mg/m2 BSA 5FU over 24 h, one course with 700 mg/m2 BSA amifostine prior to the 5-FU infusion and the other without."( Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
Fuhlroth, J; Martens-Lobenhoffer, J; Ridwelski, K, 2000
)
0.31
"Cytoprotection of healthy cells represents a new approach in cancer chemotherapy, but a pharmacokinetic drug interaction between the cytostatic and the cytoprotectant is undesired."( Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine.
Czejka, M; Eder, I; Freitag, R; Kraule, C; Reznicek, G; Schueller, J; Zeleni, U,
)
0.13
"In both treatment schedules the steady state of PACLI occurred after 3 hours, the tmax of metabolites between 3 and 4 hours."( Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine.
Czejka, M; Eder, I; Freitag, R; Kraule, C; Reznicek, G; Schueller, J; Zeleni, U,
)
0.13
" We conducted a clinical and pharmacokinetic pilot study to assess the feasibility and toxicity of the docetaxel plus amifostine combination and the absence of influence of amifostine on docetaxel pharmacokinetics."( Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
Awada, A; Brassinne, C; de Valeriola, D; Freyer, G; Gil, T; Hennebert, P; Kerger, J; Piccart, M; Selleslags, J, 2002
)
0.31
" A large intra-individual pharmacokinetic of topotecan between cycles 1 and 2 was also observed."( No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
Malmström, H; Peterson, C; Zackrisson, AL, 2002
)
0.31
" The non-irradiated mouse was used for pharmacokinetic and behavioural tests."( Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets.
Kumar, KS; Landauer, MR; Pendergrass, JA; Seed, TM; Srinivasan, V, 2002
)
0.31
" Pharmacokinetic data and locomotor activity suggest that the implantation was beneficial though radioprotection data warrants formulation improvements in implants."( Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets.
Kumar, KS; Landauer, MR; Pendergrass, JA; Seed, TM; Srinivasan, V, 2002
)
0.31
" Preliminary data from studies of SC amifostine in monkeys indicate a plasma pharmacokinetic profile similar to that reported earlier in humans."( Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
Bachy, CM; Cassatt, DR; Fazenbaker, CA; Kifle, G, 2002
)
0.31
" A significantly higher Cmax was observed for patients receiving PAC + AMI versus PAC alone."( Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel.
Alberola, V; Juan, O; Rocher, A; Sánchez, A; Sánchez, JJ, 2005
)
0.33
"We evaluated the pharmacokinetics of amifostine and WR1065 in pediatric patients with newly diagnosed medulloblastoma to assess the influence of patient covariates, including demographics, clinical characteristics, and genetic polymorphisms, on amifostine and WR1065 pharmacokinetic parameters."( Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
Bai, F; Fouladi, M; Gajjar, A; McKibbin, T; Okcu, MF; Panetta, JC; Stewart, CF, 2010
)
0.36
" A pharmacokinetic model was simultaneously fit to amifostine and WR1065 plasma or whole blood concentration-versus-time data."( Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
Bai, F; Fouladi, M; Gajjar, A; McKibbin, T; Okcu, MF; Panetta, JC; Stewart, CF, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" These results with a small number of patients suggest that amifostine given with carboplatin may reduce the duration of thrombocytopenia and hospitalisation."( Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
Anderson, H; Betticher, DC; Meely, K; Oster, W; Ranson, M; Thatcher, N, 1995
)
0.29
" In this pilot study, we tested the feasibility of MMC/VBL administration in combination with amifostine and we monitored the hematologic toxicity closely."( Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997
)
0.3
"Twenty patients with advanced ovarian cancer were treated with chemotherapy PC (cisplatin 100 mg/m2, cyclophosphamide 1000 mg/m2) administered with amifostine."( [Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer].
Pawlicki, M; Rolski, J; Rychlik, U; Wiczyńska, B, 1998
)
0.3
"We evaluated the influence of amifostine used alone or in combination with 2-chlorodeoxyadenosine (2-CdA) on the colony growth of normal and chronic myeloid leukemia (CML) granulocyte-macrophage progenitor cells (CFU-GM) in semisolid culture in vitro."( The influence of amifostine used alone or in combination with 2-chlorodeoxyadenosine on normal and chronic myelogenous leukemia granulocyte-macrophage progenitor cells in vitro.
Korycka, A; Robak, T, 2000
)
0.31
"Ten anemic patients with favorable myelodysplastic syndrome (MDS) were first treated with two 5-week courses of amifostine alone (each course consisted of 200 mg/m(2) of the drug given intravenously three times a week for 3 weeks), followed by an additional two courses combined with subcutaneous erythropoietin (EPO) (150 U/kg, three times a week for 8 weeks)."( Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome.
Dispenzieria, A; Elliott, MA; Hanson, CA; Hook, CC; Letendre, L; Schroeder, G; Steensma, DP; Tefferi, A, 2001
)
0.31
" We have treated 10 patients with 250 mg/m2 amifostine thrice weekly in combination with erythropoietin for 4 consecutive weeks followed by 2 weeks observation."( Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome.
Eibl, M; Jaeger, G; Linkesch, W; Neumeister, P; Sormann, S; Zinke, W, 2001
)
0.31
"Amifostine can be given safely at a dose of 910 mg/m2 four times in 1 day in combination with HD-CTX."( Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide.
Bosshard, M; Cavalli, F; Egger, HP; Gabutti, L; Ghielmini, M; Kiess, M; Pampallona, S; Sessa, C; Van der Bosch, S, 2001
)
0.31
" Eight patients were included in the study: six received paclitaxel in combination with epirubicin and cisplatin, and two received paclitaxel as a single agent."( Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Beijnen, JH; Hoekman, K; Huijskes, RV; Nannan Panday, VR; Rosing, H; Van den Brande, J; Verheijen, RH; Vermorken, JB, 2001
)
0.31
" Therapeutic glucan treatment administered in combination with preirradiation WR-2721 or WR-3689 treatment synergistically increases both hematopoietic reconstitution and survival."( Radioprotection by polysaccharides alone and in combination with aminothiols.
Brook, I; D'Alesandro, MM; MacVittie, TJ; Patchen, ML; Solberg, BD, 1992
)
0.28
" The MTD for irinotecan administered in combination with cisplatin (30 mg/m(2)) was 50 mg/m(2)."( Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Bernstein, ML; Blaney, SM; Dubowy, RL; Hershon, L; McLeod, WD; Souid, AK; Sullivan, J, 2003
)
0.32
"The aim of this study was to investigate the curative effect of amifostine (AMF) combined with recombinant human erythropoietin (rhEPO) on the aged patients with myelodysplastic syndrome."( [Short-term curative effect of amifostine combined with rhEPO on aged patients wilh myelodysplastic syndrome].
Fan, H; Lu, XC; Yang, Y; Yao, SQ; Zhu, HL; Zhuang, XM, 2005
)
0.33
"High-dose cisplatin combined with etoposide and bleomycin (HDPEB) improves event-free survival (EFS) in advanced pediatric germ-cell tumors (PGCT), but has significant ototoxicity."( Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Billmire, DF; Chang, KW; Davis, MM; Frazier, AL; Giller, R; Lauer, SJ; London, WB; Malogolowkin, M; Marina, N; Olson, TA; Perlman, EJ; Rescorla, F; Womer, RB, 2005
)
0.33
" In conclusion, the individualized protocol of fludarabine combined with rituximab and amifostine showed the safety and effectiveness for treatment of aged patient with CLL."( [Curative efficacy of fludarabine combined with rituximab and amifostine on aged patient with B-chronic lymphocytic leukemia].
Li, SX; Liu, Y; Lu, XC; Zhu, HL, 2007
)
0.34
" In the present study, the feasibility of hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) in combination with vinorelbine and liposomal doxorubicin was evaluated."( Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Bouros, D; Froudarakis, ME; Koukourakis, MI; Tsoutsou, PG,
)
0.13
"The aim of this study was to investigate the curative effects of amifostine (AMF) combined with recombinant human beta-erythropoietin (rhbeta-EPO) on patients with pure erythroid aplasia (PEA)."( [Short-term curative effect of amifostine combined with rhbeta-EPO on patients with pure erythroid aplasia].
Fan, H; Guo, B; Li, SX; Lu, XC; Zhai, B; Zhu, HL, 2008
)
0.35
"Metformin, a biguanide drug used in the treatment of type II diabetes, was evaluated alone and in combination with amifostine, captopril, MESNA or N-acetyl-cysteine (NAC) for its ability to protect when administered 24 h after irradiation."( Metformin exhibits radiation countermeasures efficacy when used alone or in combination with sulfhydryl containing drugs.
Grdina, DJ; Miller, RC; Murley, JS, 2014
)
0.4
" polysaccharide (SNP) in combination with WR-2721, rhIL-11 and rhG-CSF on irradiated mice."( Radioprotective effects of Sipunculus nudus L. polysaccharide combined with WR-2721, rhIL-11 and rhG-CSF on radiation-injured mice.
Chen, W; He, Y; Jiang, D; Jiang, S; Liu, Y; Shen, X, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
"We have investigated the disposition of ethiofos (20 mg, 4 microCi [14C]ethiofos) in the isolated perfused rat liver preparation to determine the hepatic contribution to the poor oral bioavailability of the drug."( The disposition of ethiofos (WR-2721) in the isolated perfused rat liver.
Brewer, TG; Coleman, MD; Fleckenstein, L; Geary, RS; Mangold, DJ; Timony, GA, 1989
)
0.28
" Analysis of the free WR-1065 bioavailability values indicated large variability and an unpredictable dose response among subjects."( Intraduodenal administration of ethiofos (WR-2721): dose proportionality study in the rhesus monkey.
Geary, RS; Ludden, T; Mangold, DJ; Miller, MA; Swynnerton, NF, 1989
)
0.28
" It is well absorbed (23%) after oral administration to rabbits."( Studies on the reduction of sputum viscosity in cystic fibrosis using an orally absorbed protected thiol.
Cerami, A; Peterson, CM; Tabachnik, NF, 1980
)
0.26
" A pilot pharmacokinetic evaluation of subcutaneous administration of amifostine in 12 healthy male volunteers compared the relative bioavailability of 500 mg of amifostine administered subcutaneously with that of 200 mg/m2 given intravenously."( Pharmacokinetics of amifostine: effects of dose and method of administration.
Bonner, HS; Lieberman, R; Schiller, J; Schuchter, L; Shaw, LM, 1999
)
0.3
" Bioavailability of amifostine (parent drug) and its pharmacologically active metabolite, WR-1065, was evaluated by comparing the area under the concentration-time curve (AUC) derived from HPLC analysis of amifostine and both protein-free and protein-bound WR-1065 in all three routes of administration."( New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
Bonner, HS; Shaw, LM, 2002
)
0.31
" This is a strong indicator of similar bioavailability in mice from both routes of administration."( Oral administration is as effective as intraperitoneal administration of amifostine in decreasing nitroxide EPR signal decay in vivo.
Elas, M; Grdina, DJ; Halpern, HJ; Parasca, A, 2003
)
0.32
" Although human patient data indicate higher plasma bioavailability of the active metabolite (WR-1065) following intravenous compared to subcutaneous administration, there are no corresponding data showing human tissue levels of WR-1065 following either route of administration due to the difficulty in obtaining human specimens."( Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
Bachy, CM; Cassatt, DR; Fazenbaker, CA; Kifle, G; McCarthy, MP, 2004
)
0.32
" The cationic charge (due to the presence of chitosan) of these particles is expected to favour oral absorption and thus overall bioavailability of orally administered amifostine."( Preparation of polylactide-co-glycolide and chitosan hybrid microcapsules of amifostine using coaxial ultrasonic atomizer with solvent evaporation.
Bostanian, LA; Graves, RA; Kishore, V; Mandal, TK; Moiseyev, R; Pamujula, S, 2008
)
0.35
"This study shows the effect of ion pair formation on intestinal absorption and oral bioavailability of amifostine."( Ion-pair strategy for enabling amifostine oral absorption: rat in situ and in vivo experiments.
Bermejo, M; Foroutan, M; González-Álvarez, I; Mangas-Sanjuan, V; Samiei, N; Shafaati, A; Zarghi, A, 2013
)
0.39
" Direct jejunal AMF administration incurred a systemic bioavailability of 61."( Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
Buchman, L; Buchman, SR; Donneys, A; Lipka, E; Lynn, J; Nelson, N; Ranganathan, K; Reyna, D; Rodriguez, J; Simon, E; Snider, A; Zhang, Y, 2018
)
0.48
"Orally administered AMF achieves a similar systemic bioavailability and decreased peak plasma level of WR-1065 compared to intravenously administered AMF, suggesting oral AMF formulations maintain radioprotective efficacy without causing onerous side effects, and are clinically feasible."( Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
Buchman, L; Buchman, SR; Donneys, A; Lipka, E; Lynn, J; Nelson, N; Ranganathan, K; Reyna, D; Rodriguez, J; Simon, E; Snider, A; Zhang, Y, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" A regimen of 15 doses of WR2721, 200 mg/kg prior to antibody infusion followed by 100 mg/kg ip every 4 h for a total of 72 h, was the maximum tolerated dosage schedule."( WR2721 protection of bone marrow in 131I-labeled antibody therapy.
Badger, CC; Bernstein, ID; Fisher, DR; Hui, TE; Nourigat, C; Rasey, J; Wu, ZM, 1991
)
0.28
"05), but at 75 j/cm2 irradiation only the 750 mg/kg dosage remained protective."( The protection of hemopoietic mice progenitors by WR-2721 during photodynamic therapy.
Foultier, MT; Le Bodic, L; Maloisel, F; Oberling, F; Patrice, T; Praloran, V, 1990
)
0.28
" As the dosage of 90Y-CO17-1A increased, the rate of tumor growth decreased, but all experimental animals in this group died between 14 and 21 days."( Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques.
Byrd, BL; Crook, JE; Holloway, EC; Lee, YC; Steplewski, Z; Sun, TT; Washburn, LC, 1990
)
0.28
" Therapeutic strategies aimed at reducing toxicity and allowing dose escalation of intravenous cisplatin, such as administration in hypertonic saline and pharmacokinetically based dosing schedules, have been partially successful in reducing nephrotoxicity and bone marrow suppression."( Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate.
DeGregorio, MW; Gandara, DR; Makuch, RW; Perez, EA; Wiebe, VJ, 1990
)
0.28
" Both slopes of the dose-response regression line are parallel in effect."( Effect of the radioprotector WR-2721 on operant behavior in the rat.
Lee, JD; Lee, SF; Lin, CH; Liu, WF; Ma, C; Shih, JH,
)
0.13
" In the third experiment, which looked at the dose-response curve for amphetamine-induced taste aversion learning in intact rats and rats with area postrema lesions, it was shown that both groups of rats acquired taste aversions following injection of amphetamine, although the rats with lesions showed a less severe aversion than the intact rats."( Interactions between radiation and amphetamine in taste aversion learning and the role of the area postrema in amphetamine-induced conditioned taste aversions.
Hunt, WA; Lee, J; Rabin, BM, 1987
)
0.27
" Cell survival curves and dose-response curves for radiation alone and drug with radiation were constructed over the dose range of ."( Protection of mouse bone marrow by WR-2721 after fractionated irradiation.
Basic, I; Fang, MZ; Travis, EL, 1988
)
0.27
" However, at concentrations less than 200 mg/kg, the radioprotective effect decreased in a dose-response manner with a concentration of 150 mg/kg providing 50% of the maximum effect observed."( Radiation protection of rat parenchymal hepatocytes with S-2-(3-aminopropylamino)ethylphosphorothioic acid.
Crocker, IR; Jirtle, RL; Pierce, LJ; Strom, SC, 1985
)
0.27
" Skin reactions, four different kidney assays, regrowth delay and local control of tumours have been used to construct dose-response curves from which the degree of radioprotection can be quantified as a protection factor."( Fractionation studies with WR-2721: normal tissues and tumour.
Denekamp, J; Rojas, A; Smith, KA; Soranson, JA; Stewart, FA, 1986
)
0.27
" This analytical procedure and others specific for ethiofos, free WR-1065 and WR-33278 were applied to dosing experiments in which the parent drug and its major metabolites were variously administered to beagle dogs and rhesus monkeys."( A method for the combined measurement of ethiofos and WR-1065 in plasma: application to pharmacokinetic experiments with ethiofos and its metabolites.
Huelle, BK; Ludden, TM; Mangold, DJ; Swynnerton, NF, 1986
)
0.27
"Melphalan has a steep dose-response curve, but the use of high doses results in unacceptable myelosuppression."( A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
Adamson, PC; Balis, FM; Belasco, JE; Berg, SL; Blaney, SM; Craig, C; Lange, B; Poplack, DG, 1995
)
0.29
" A number of different paradigms of dosing route and schedule for the administration of the two agents have been investigated."( Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma.
Chaney, SG; Holbrook, DJ; Thompson, DC; Wyrick, SD, 1995
)
0.29
" These observations offer the promise of using high doses of chemotherapy to exploit antitumor, dose-response relationships in clinical trials."( Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi, RL; Scheffler, BJ; Schein, PS, 1993
)
0.29
" The dosing and administration guidelines are reviewed."( Amifostine (Ethyol): dosing, administration and patient management guidelines.
Bukowski, RM, 1996
)
0.29
" Multiple dosing resulted in a tendency toward increasing peak levels of WR 1065 and decreasing peak levels of the disulfides."( Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Gall, HE; Korst, AE; van der Vijgh, WJ; Vermorken, JB, 1996
)
0.29
"The mechanism of action, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of amifostine are reviewed."( Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora, JA; Siden, R, 1997
)
0.3
" Doxorubicin, vincristine, etoposide, cisplatin, 4-hydroperoxycyclophosphamide and 4-hydroperoxyifosfamide were equally cytotoxic with and without preincubation of WR-2721 (14 mM) or WR-1065 (40 microM) as shown by virtually identical dose-response curves and ID50 values."( Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro.
Berthold, F; Fulda, S; Oster, W, 1997
)
0.3
" The amifostine peak values at the end of each 15 min infusion did not accumulate in the multiple dosing schedule."( Pharmacokinetics of amifostine and its metabolites in patients.
Eeltink, CM; Korst, AE; van der Vijgh, WJ; Vermorken, JB, 1997
)
0.3
" Future studies should be focused on both new indications like childhood cancer, myelodysplastic syndromes, dose-intensified or high- dose chemotherapy, and multimodality approaches and optimization of amifostine dosage in order to reduce dose-limiting side effects."( Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher, CM; Mallmann, PK,
)
0.13
" Instead, patients in the control arms of some of the trials have been exposed to more prolonged use or increased dosage of toxic chemotherapy that placed them at greater risk of the toxicity the protective agent was designed to prevent (eg, cardiotoxicity in trials of dexrazoxane, myelosuppression or thrombocytopenia in trials of growth factors)."( Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.
Phillips, KA; Tannock, IF, 1998
)
0.3
" The optimal dosing regimen with amifostine and carboplatin needs to be further evaluated in clinical studies."( Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
Budd, GT; Bukowski, RM; Ganapathi, R; McLain, D; Snyder, J; Wood, L, 1999
)
0.3
"Numerous dosing regimens have been used in the clinical development of amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA)."( Dosing considerations with amifostine: a review of the literature and clinical experience.
Dorr, RT; Holmes, BC, 1999
)
0.3
"Mesna: (1) Mesna, dosed as detailed in these guidelines, is recommended to decrease the incidence of standard-dose ifosfamide-associated urothelial toxicity."( American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Broder, G; Cohen, GI; Gradishar, WJ; Green, DM; Hensley, ML; Langdon, RJ; Lindley, C; Meropol, NJ; Mitchell, RB; Negrin, R; Pfister, DG; Schuchter, LM; Szatrowski, TP; Thigpen, JT; Von Hoff, D; Wasserman, TH; Winer, EP, 1999
)
0.3
"The dose-response radioprotectant effects of amifostine on rat growth plate have not been studied."( Dose response of amifostine in protection of growth plate function from irradiation effects.
Damron, LA; Damron, TA; Margulies, B; Spadaro, JA, 2000
)
0.31
" 5-FU chemotherapy was administered as 120-hours continuous infusion in the first and fifth radiation week via a central venous catheter in a daily dosage of 1,000 mg/m2."( Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
Dunst, J; Müller, AC; Pigorsch, S; Reese, T; Semlin, S, 2000
)
0.31
" Adequate dosing of either drug is necessary for protecting the cells from toxic effects of alkylating agents."( Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
Aktas, MK; Bernstein, ML; Dubowy, RL; Fahey, RC; Karjoo, S; Newton, GL; Sadowitz, PD; Sayin, OA; Souid, AK, 2001
)
0.31
" Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e."( A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Abeloff, MD; Glover, DJ; Gradishar, WJ; Moore, MR; Neuberg, DS; Piel, I; Stephenson, P; Windschitl, HE, 2001
)
0.31
" Nontumor-bearing control animals were sham treated using the same dosing and surgery schedules."( Inhibition of spontaneous metastases formation by amifostine.
Grdina, DJ; Hunter, N; Kataoka, Y; Milas, L; Murley, JS; Weichselbaum, RR, 2002
)
0.31
"A phase I clinical trial was conducted to assess thefeasibility of a more convenient and safe dosing regime for the cytoprotective drug amifostine."( New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
Bonner, HS; Shaw, LM, 2002
)
0.31
" The doses of each drug were appropriately calculated on the basis of other experiments in the literature and given in analogous dosage to human kilograms of body weight."( Investigation of doxorubicin tissue toxicity: does amifostine provide chemoprotection? An experimental study.
Couris, E; Deliconstantinos, G; Dontas, I; Karayannacos, PE; Perrea-Kotsarelis, D; Rigatos, SK; Stathopoulos, GP,
)
0.13
" Also, the optimal dosage and schedule of amifostine in chemoradiation combinations have not yet been established."( Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy.
Andreassen, CN; Grau, C; Lindegaard, JC, 2003
)
0.32
" Multiple-dose studies in rats show radioprotective effects equal to or greater than those obtained with intravenous dosing in the setting of fractionated irradiation."( Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
Bachy, CM; Cassatt, DR; Fazenbaker, CA; Kifle, G, 2002
)
0.31
" Subcutaneous dosing is currently being assessed with the aim of improving ease of administration and potentially further improving tolerability."( Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
Boccia, R, 2002
)
0.31
" Nontumor-bearing control animals were treated using the same dosing and surgery schedules."( Antimetastatic effectiveness of amifostine therapy following surgical removal of Sa-NH tumors in mice.
Grdina, DJ; Hunter, N; Kataoka, Y; Lee, JY; Milas, L; Murley, JS; Swedberg, K; Weichselbaum, RR, 2002
)
0.31
" The dose-volume histogram (DVH) data were used to estimate the local dose-response relationship for loss of DL(CO)."( The relationship between local dose and loss of function for irradiated lung.
Forster, KM; Gopal, R; Kelly, JF; Komaki, R; Liao, Z; Starkschall, G; Stevens, C; Tucker, SL, 2003
)
0.32
" Side effects related to the therapy may unfavorably influence quality of life for a short or long period of time, may cause the need to decrease the dosage or shorten the overall period of treatment or survival of the patient."( [Cytoprotective effects of amifostine in the treatment of tumors].
Burkon, P; Petýrek, P; Spurný, V, 2003
)
0.32
" The lack of improved duration of response or impact on survival may be the result of the limited improvement of efficacy with the higher dosage of cisplatin in conjunction with WR-2721, or the limited number of patients accrued to this study."( Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686).
Borden, E; Ewell, M; Glick, J; Glover, D; Ibrahim, J; Karp, D; Kirkwood, J; Stewart, J, 2003
)
0.32
"The WR-1065 tumor portal dosing AUC15-60 was 40% of systemic dosing, and tumor concentrations following portal dosing were one-fifth of that following systemic dosing."( Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
DeRemer, SJ; Dou, C; Ensminger, WD; Levi, M; Smith, DE, 2004
)
0.32
" However, portal dosing also increases systemic exposure to WR-1065, which is associated with hypotension."( Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
DeRemer, SJ; Dou, C; Ensminger, WD; Levi, M; Smith, DE, 2004
)
0.32
" The need for daily dosing to achieve optimal radioprotection was consistent with the tissue pharmacokinetics of the active metabolite."( Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Bachy, CM; Cassatt, DR; Fazenbaker, CA; Kifle, G, 2003
)
0.32
" However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies."( Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Axelrod, R; Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Scott, C; Smith, C; Wasserman, T; Werner-Wasik, M, 2005
)
0.33
" 6 h after poisoning in three cumulative dosing groups: 250 mg/kg; 500 mg/kg; and 1600 mg/kg."( Use of amifostine, a novel cytoprotective, in alpha-amanitin poisoning.
Haller, NA; Peter, D; White, LJ; Wills, BK, 2005
)
0.33
" Initial experiments by the authors' group suggested that administration of each agent alone significantly increased the median latent time to radiation myelopathy (RM) in previously unirradiated animals but did not change the dose-response relationship."( Effects of insulin-like growth factor-1 (IGF-1) and amifostine in spinal cord reirradiation.
Andratschke, N; Ang, KK; Nieder, C; Price, RE; Rivera, B, 2005
)
0.33
" The shift of the dose-response curve suggests an increase of the ED(50) for single-dose treatment by approximately 7%."( Effects of insulin-like growth factor-1 (IGF-1) and amifostine in spinal cord reirradiation.
Andratschke, N; Ang, KK; Nieder, C; Price, RE; Rivera, B, 2005
)
0.33
" In addition, dose-response curves were calculated."( Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
Debus, J; Haberkorn, U; Herfarth, KK; Hof, H; Hoffner, S; Huber, P; Karger, CP; Münter, MW; Rudat, V, 2007
)
0.34
" In regard to the endpoint "reduction of the salivary gland excretion rate of more than 50%," the dose-response curves yielded D50-values of 34."( Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
Debus, J; Haberkorn, U; Herfarth, KK; Hof, H; Hoffner, S; Huber, P; Karger, CP; Münter, MW; Rudat, V, 2007
)
0.34
"To determine the radiation dose-response relationship on salivary dysfunction and quality of life (QOL) over time in patients with lymphoma receiving radiation therapy (RT) to the head and neck (H&N)."( A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation.
Hickey, G; Killion, L; Martin, C; Mauch, PM; Ng, AK; Rodrigues, NA; Silver, B; Stevenson, MA, 2009
)
0.35
" These pre-clinical findings provide proof-of-principle to further delineate specific mechanisms underlying amifostine's beneficial effects, determine optimal amifostine-radiation therapy dosing regimens, and thereby expedite translation into clinical trials to reduce lymphedema incidence and severity in cancer patients at high lymphedema risk in whom radiation therapy is the recommended therapy."( Radioprotection from radiation-induced lymphedema without tumor protection.
Bernas, MJ; Bracamonte, F; Daley, SK; Hirleman, ED; McKenna, M; Stea, BD; Stejskal, A; Witte, MH, 2010
)
0.36
" In order to prevent the side effects associated with amifostine treatment, an alternative dosing and anti-emetic regimen was developed as part of this protocol, which significantly improved patient acceptance."( Efficacy of amifostine in treating patients with idiopathic thrombocytopenia purpura.
Fan, H; Guo, B; Li, SX; Liu, Y; Lu, XC; Yao, SQ; Zhai, B; Zhu, HL, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"At the moment there is no evidence from individual studies in children with osteosarcoma and hepatoblastoma treated with different platinum analogues and dosage schedules which underscores the use of amifostine as an otoprotective intervention as compared to no additional treatment."( Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As, JW; van Dalen, EC; van den Berg, H, 2012
)
0.38
" Irradiated animals received a fractionated dosing schedule of 35 Gy, with amifostine-pretreated animals receiving amifostine before irradiation."( Prophylactic amifostine preserves the biomechanical properties of irradiated bone in the murine mandible.
Ahsan, S; Buchman, SR; Deshpande, SS; Donneys, A; Felice, PA; Kozloff, KM; Nelson, NS; Perosky, JE, 2014
)
0.4
"At the moment there is no evidence from individual studies in children with osteosarcoma or hepatoblastoma treated with different platinum analogues and dosage schedules which underscores the use of amifostine as an otoprotective intervention as compared to no additional treatment."( Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As, JW; van Dalen, EC; van den Berg, H, 2014
)
0.4
"A biweekly administration of sustained-release microsphere dosage form of amifostine, a radioprotective drug used in radiotherapy, was performed to examine the feasibility to minimize injection frequency and blood concentration-associated side effects."( Sustained-release microspheres of amifostine for improved radio-protection, patient compliance, and reduced side effects.
Hu, ZH; Jin, T; Wu, HY, 2016
)
0.43
"Two groups of murine left hemimandibles were exposed to a human equivalent radiation dosage fractionated over 5 daily doses of 7 Gy."( Radioprotection With Amifostine Enhances Bone Strength and Regeneration and Bony Union in a Rat Model of Mandibular Distraction Osteogenesis.
Buchman, SR; Dahle, SE; Deshpande, SS; Donneys, A; Goldstein, SA; Monson, LA; Nelson, NS; Sarhaddi, D; Tchanque-Fossuo, CN, 2018
)
0.48
" This study compared the effects of a single dose (75 mg/kg) of CYP with effects generated by fractionated dosing of CYP (5 doses of 15 mg/kg), a dosing approach often used during chemotherapy, on the taste system of mice using immunohistochemistry."( Cyclophosphamide and the taste system: Effects of dose fractionation and amifostine on taste cell renewal.
Delay, ER; Delay, RJ; Girardin, JL; Jewkes, BC; King, JH; Socia, SH, 2019
)
0.51
"Amifostine is a cytoprotective agent against the hematopoietic damage induced by ionizing radiation, although the intravenous injection of amifostine is a unique administration method with strict dosing time limitation."( Amifostine-loaded armored dissolving microneedles for long-term prevention of ionizing radiation-induced injury.
Fang, R; Jin, Y; Li, J; Li, M; Wu, Z; Yu, X; Zhang, G; Zhu, L, 2020
)
0.56
" Unfortunately, acute radiation disease will occur if the human body is accidentally exposed to a large dosage of ionizing radiation."( Reactive oxygen species-responsive nanodrug of natural crocin-i with prolonged circulation for effective radioprotection.
Cao, Y; He, W; Hua, D; Kuang, L; Liu, C; Wang, L; Yin, J; Zhang, X, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
radiation protective agentAny compound that is able to protect normal cells from the damage caused by radiation therapy.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
diamineAny polyamine that contains two amino groups.
organic thiophosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency1.68340.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency8.91250.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency251.18900.540617.639296.1227AID2364; AID2528
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.01120.00106.000935.4813AID943
Cellular tumor antigen p53Homo sapiens (human)Potency6.68240.002319.595674.0614AID651631
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency7.07950.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)1.92900.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.65500.00000.602010.0000AID625254
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (164)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (149)

Assay IDTitleYearJournalArticle
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1243476Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as incidence of micronuclei in binucleated cells at 4.7 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay (Rvb = 2015Journal of natural products, Sep-25, Volume: 78, Issue:9
Phenolic Compounds from Atriplex littoralis and Their Radiation-Mitigating Activity.
AID447557Radioprotective activity against gamma radiation-induced toxicity in Swiss CD1 mouse assessed as survival at 400 mg/kg, ip administered 90 mins before 10.2 Gy irradiation measured after 30 days2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Synthesis, antioxidant properties and radioprotective effects of new benzothiazoles and thiadiazoles.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1299700Induction of DNA damage in gamma irradiated human MCF7 cells assessed as median number of gammaH2AK/53BP1 foci per nucleus at 4 mM preincubated for 15 mins followed by gamma irradiation measured after 5 mins by confocal fluorescence microscopic analysis r2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1299719Ratio of prodrug conversion in human NHDF assessed as ALP-mediated WR-1065 formation at 75 mins to prodrug conversion in human MCF7 cells assessed as ALP-mediated WR-1065 formation at 75 mins2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID111157Radioprotective effects in mice when administered i.p. at 50% LD50, 15 min prior to whole body radiation.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and radioprotective activity of new cysteamine and cystamine derivatives.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1399357Antioxidant activity assessed as trolox equivalent of hydroxyl radical scavenging activity by DMPO spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1299711Prodrug conversion in human MCF7 cells assessed as ALP-mediated WR-1065 formation at 4 mM after 20 to 75 mins by LC-MS/MS analysis2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1243448Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as binucleated cells with micronuclei at 4.7 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay (Rvb = 15.5 +/- 0.2015Journal of natural products, Sep-25, Volume: 78, Issue:9
Phenolic Compounds from Atriplex littoralis and Their Radiation-Mitigating Activity.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1299712Induction of DNA damage in gamma irradiated human MCF7 cells assessed as increase in median number of gammaH2AK/53BP1 foci per nucleus at 4 mM preincubated for 15 mins followed by gamma irradiation measured after 60 to 120 mins by confocal fluorescence mi2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID1399362Antioxidant activity assessed as trolox equivalent of methyl radical scavenging activity by DMPO spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID1299703Reduction of DNA DSB repair in gamma irradiated human MCF7 cells assessed as median number of gammaH2AK/53BP1 foci per nucleus at 4 mM preincubated for 15 mins followed by gamma irradiation measured after 60 mins by confocal fluorescence microscopic analy2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID1299720Ratio of prodrug conversion in human NHDF supernatants assessed as ALP-mediated WR-1065 formation at 75 mins to prodrug conversion in human MCF7 cell supernatants assessed as ALP-mediated WR-1065 formation at 75 mins2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID120747Percent survival against percutaneously administered sulfur mustard in mice (38.7 mg/kg) after 7 days.2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Novel S-substituted aminoalkylamino ethanethiols as potential antidotes against sulfur mustard toxicity.
AID1299714Induction of DNA DSB repair in gamma irradiated human NHDF assessed as median number of gammaH2AK/53BP1 foci per nucleus preincubated for 15 mins followed by gamma irradiation measured after 120 mins by confocal fluorescence microscopic analysis relative 2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID1299718Ratio of prodrug conversion in human NHDF supernatants assessed as ALP-mediated WR-1065 formation at 20 mins to prodrug conversion in human MCF7 cell supernatants assessed as ALP-mediated WR-1065 formation at 20 mins2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID136324The percentage 30-day survival of the mice at 600 mg/kg dose, with the radiation dose of 10 GY.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
S-[2-[(2'-carbamoylethyl)amino]ethyl] phosphorothioate and related compounds as potential antiradiation agents.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID292724Survival of NMRI mouse subcutaneously dosed 30 mins before cobalt 60 gamma irradiation2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Kojic acid and its manganese and zinc complexes as potential radioprotective agents.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID447538Acute toxicity in Swiss CD1 mouse assessed as lethality after 48 hrs2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Synthesis, antioxidant properties and radioprotective effects of new benzothiazoles and thiadiazoles.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1299706Induction of DNA DSB repair in gamma irradiated human NHDF at 4 mM preincubated for 15 mins followed by gamma irradiation measured after 60 to 120 mins by neutral comet assay2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID1388987Protection against cisplatin-induced ototoxicity in human assessed as reduction in hearing loss administered iv 35 mins prior to cisplatin treatment2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.
AID117226LD50 following oral dosing.2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Novel S-substituted aminoalkylamino ethanethiols as potential antidotes against sulfur mustard toxicity.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID292723Survival of NMRI mouse for 30 days at 214 mg/kg, sc administered 24 hrs before cobalt 60 gamma irradiation2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Kojic acid and its manganese and zinc complexes as potential radioprotective agents.
AID1243488Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as frequency of micronuclei at 4.7 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay relative to control2015Journal of natural products, Sep-25, Volume: 78, Issue:9
Phenolic Compounds from Atriplex littoralis and Their Radiation-Mitigating Activity.
AID1399358Antioxidant activity assessed as trolox equivalent of alkoxyl radical scavenging activity by DMPO spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID1399359Antioxidant activity assessed as trolox equivalent of tert-butyl peroxyl radical scavenging activity by CYPMPO spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID447542Radioprotective activity against gamma radiation-induced toxicity in B6D2F1 mouse assessed as survival at 400 mg/kg, ip administered 15 mins before 8.8 Gy irradiation measured after 30 days2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Synthesis, antioxidant properties and radioprotective effects of new benzothiazoles and thiadiazoles.
AID1299698Protection against DNA damage in gamma irradiated human NHDF assessed as decrease in median number of gammaH2AX/53BP1 foci per nucleus at 4 mM preincubated for 15 mins followed by gamma irradiation measured after 60 mins by confocal fluorescence microscop2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1299717Ratio of prodrug conversion in human NHDF assessed as ALP-mediated WR-1065 formation at 20 mins to prodrug conversion in human MCF7 cells assessed as ALP-mediated WR-1065 formation at 20 mins2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID111158Radioprotective effects in mice when administered i.p. at 50% LD50, 2 hr prior to whole body radiation.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and radioprotective activity of new cysteamine and cystamine derivatives.
AID1299697Protection against DNA damage in gamma irradiated human NHDF assessed as decrease in median number of gammaH2AX/53BP1 foci per nucleus at 4 mM preincubated for 15 mins followed by gamma irradiation measured after 5 mins by confocal fluorescence microscopi2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID136316The percentage 30-day survival of the mice at 150 mg/kg dose, with the radiation dose of 10 Gy.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
S-[2-[(2'-carbamoylethyl)amino]ethyl] phosphorothioate and related compounds as potential antiradiation agents.
AID447535Antioxidant activity assessed as DPPH free radical scavenging activity by UV spectroscopic method2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Synthesis, antioxidant properties and radioprotective effects of new benzothiazoles and thiadiazoles.
AID136326The percentage 30-day survival of the mice at 75 mg/kg dose, with the radiation dose of 10 Gy.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
S-[2-[(2'-carbamoylethyl)amino]ethyl] phosphorothioate and related compounds as potential antiradiation agents.
AID447543Radioprotective activity against gamma radiation-induced toxicity in B6D2F1 mouse assessed as survival at 400 mg/kg, ip administered 15 mins before 10.8 Gy irradiation measured after 30 days2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Synthesis, antioxidant properties and radioprotective effects of new benzothiazoles and thiadiazoles.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1399360Antioxidant activity assessed as trolox equivalent of superoxide radical scavenging activity by CYPMPO spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID116918Lethal dose in mice (LD50)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and radioprotective activity of new cysteamine and cystamine derivatives.
AID118097Percent survival against percutaneously administered sulfur mustard in mice (38.7 mg/kg) after 14 days.2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Novel S-substituted aminoalkylamino ethanethiols as potential antidotes against sulfur mustard toxicity.
AID111161Radioprotective effects in mice when administered i.p. at 12.5% LD50, 15 min prior to whole body radiation.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and radioprotective activity of new cysteamine and cystamine derivatives.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID136319The percentage 30-day survival of the mice at 300 mg/kg dose, with the radiation dose of 10 GY.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
S-[2-[(2'-carbamoylethyl)amino]ethyl] phosphorothioate and related compounds as potential antiradiation agents.
AID1243435Toxicity in 2-Gy gamma irradiated human PBL assessed as cytokinesis-block proliferation index at 4.7 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs (Rvb = 1.6 +/- 0.1 No_unit)2015Journal of natural products, Sep-25, Volume: 78, Issue:9
Phenolic Compounds from Atriplex littoralis and Their Radiation-Mitigating Activity.
AID447556Radioprotective activity against gamma radiation-induced toxicity in Swiss CD1 mouse assessed as survival at 400 mg/kg, ip administered 90 mins before 8.2 Gy irradiation measured after 30 days2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Synthesis, antioxidant properties and radioprotective effects of new benzothiazoles and thiadiazoles.
AID292725Increase in survival of subcutaneously dosed NMRI mouse irradiated with cobalt 60 gamma relative to control2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Kojic acid and its manganese and zinc complexes as potential radioprotective agents.
AID1243461Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as incidence of micronuclei in 1000 binucleated cells at 4.7 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay (R2015Journal of natural products, Sep-25, Volume: 78, Issue:9
Phenolic Compounds from Atriplex littoralis and Their Radiation-Mitigating Activity.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1299707Reduction of DNA DSB repair in gamma irradiated human MCF7 cells at 4 mM preincubated for 15 mins followed by gamma irradiation measured after 60 to 120 mins by neutral comet assay2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1299710Prodrug conversion in human NHDF cells assessed as ALP-mediated WR-1065 formation at 4 mM after 20 to 75 mins by LC-MS/MS analysis2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID134405Antiradiation tests were performed in groups of 10 mice against lethal gamma-radiation 30 min after intraperitoneal dosing. Lethal dose that causes toxic deaths in mice.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
S-[2-[(2'-carbamoylethyl)amino]ethyl] phosphorothioate and related compounds as potential antiradiation agents.
AID1399363Antioxidant activity assessed as rate of methyl radical scavenging activity by DMPO spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID383550Toxicity against sc dosed NMRI mouse2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
5,7-Dihydroxychromone-2-carboxylic acid and it's transition-metal (Mn and Zn) chelates as non-thiol radioprotective agents.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1299704Protection against DNA damage in gamma irradiated human NHDF assessed as decrease in double strand breakage of DNA at 4 mM preincubated for 15 mins followed by gamma irradiation measured after 5 mins by neutral comet assay2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID1299699Induction of DNA DSB repair in gamma irradiated human NHDF assessed as decrease in median number of gammaH2AK/53BP1 foci per nucleus at 4 mM preincubated for 15 mins followed by gamma irradiation measured after 60 mins by confocal fluorescence microscopic2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID1299708Prodrug conversion in human NHDF supernatants assessed as ALP-mediated WR-1065 formation at 4 mM after 20 to 75 mins by LC-MS/MS analysis2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID1299709Prodrug conversion in human MCF7 cell supernatants assessed as ALP-mediated WR-1065 formation at 4 mM after 20 to 75 mins by LC-MS/MS analysis2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.
AID1399361Antioxidant activity assessed as trolox equivalent of singlet oxygen scavenging activity by TMPD spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID383553Radioprotective activity against gamma-irradiation in NMRI mouse assessed as survival at 0.5 mmol/kg, sc administered 1 hr prior to irradiation measured after 30 days2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
5,7-Dihydroxychromone-2-carboxylic acid and it's transition-metal (Mn and Zn) chelates as non-thiol radioprotective agents.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,482)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990308 (20.78)18.7374
1990's345 (23.28)18.2507
2000's552 (37.25)29.6817
2010's223 (15.05)24.3611
2020's54 (3.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 6.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index6.97 (24.57)
Research Supply Index7.54 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (6.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials249 (15.22%)5.53%
Reviews248 (15.16%)6.00%
Case Studies36 (2.20%)4.05%
Observational0 (0.00%)0.25%
Other1,103 (67.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]